Celldex Therapeutics, Inc. (CLDX) vs SELLAS Life Sciences Group, Inc. (SLS)
A side-by-side comparison of Celldex Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLDX
Celldex Therapeutics, Inc.
$31.00HealthcareDelayed quote: Oct 6, 2026, 2:15 PM EDT
SLS
SELLAS Life Sciences Group, Inc.
$11.39HealthcareDelayed quote: Oct 6, 2026, 2:10 PM EDT
Total return — CLDX vs SLS
growth of $100 · dividends reinvested · last 10yCLDX -49.1% (-6.5%/yr)SLS -99.9% (-48.7%/yr)CLDX compounded faster over this window
Log scale — wide-divergence pair
CLDX SLS
CLDX vs SLS: by the numbers
- •SLS is the larger company ($2.12B vs $2.06B market cap).
- •Both run net losses; SLS's is the smaller (0.00% vs -268385.71% net margin).
Metrics side by side
Valuation
| Metric | CLDX | SLS |
|---|---|---|
| P/S ratio | 18416.90 | N/A |
| P/B ratio | 2.89 | 15.39 |
Profitability
| Metric | CLDX | SLS |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -19160.00% | 0.00% |
| Net margin | -268385.71% | 0.00% |
| ROE | -42.07% | -23.58% |
| ROIC | -45.19% | -25.45% |
Growth (annualized)
| Metric | CLDX | SLS |
|---|---|---|
| Revenue CAGR (5Y) | -58.05% | N/A |
| Total return CAGR (5Y) | -10.28% | 6.20% |
Frequently asked
- How have CLDX and SLS total returns compared?
- Over the past 10 years, CLDX delivered -6.79% and SLS delivered -49.07% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.